| Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? | |
| | |
MedLine Citation:
|
PMID: 20445580 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Viral therapy of cancer includes strategies such as viral transduction of tumour cells with 'suicide genes', using viral infection to trigger immune-mediated tumour cell death and using oncolytic viruses for their direct anti-tumour action. However, problems still remain in terms of adequate viral delivery to tumours. A role is also emerging for single-organ isolation and perfusion. Having begun with the advent of isolated limb perfusion for extremity malignancy, experimental systems have been developed for the perfusion of other organs, particularly the liver, kidneys and lungs. These are beginning to be adopted into clinical treatment pathways. The combination of these two modalities is potentially significant. Locoregional perfusion increases the exposure of tumour cells to viral agents. In addition, the avoidance of systemic elimination through the immune and reticulo-endothelial systems should provide a mechanism for increased transduction/infection of target cells. The translation of laboratory research to clinical practice would occur within the context of perfusion programmes, which are already established in the clinic. Many of these programmes include the use of vasoactive cytokines such as tumour necrosis factor-alpha, which may have an effect on viral uptake. Evidence of activation of specific anti-tumour immunological responses by intratumoural and other existing methods of viral administration raises the intriguing possibility of a locoregional therapy, with the ability to affect distant sites of disease. In this review, we examined the state of the literature in this area and summarized current findings before indicating likely areas of continuing interest. |
| | |
Authors:
|
T Pencavel; R Seth; A Hayes; A Melcher; H Pandha; R Vile; K J Harrington |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2010-05-06 |
Journal Detail:
|
Title: Gene therapy Volume: 17 ISSN: 1476-5462 ISO Abbreviation: Gene Ther. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-12 Completed Date: 2010-12-10 Revised Date: 2011-10-11 |
Medline Journal Info:
|
Nlm Unique ID: 9421525 Medline TA: Gene Ther Country: England |
Other Details:
|
Languages: eng Pagination: 949-60 Citation Subset: IM |
Affiliation:
|
Targeted Therapy Team, The Institute of Cancer Research, and Sarcoma/Melanoma Unit, Royal Marsden Hospital, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Gene Therapy / methods* Humans Neoplasms / genetics, therapy*, virology Oncolytic Virotherapy / methods* Oncolytic Viruses / genetics, physiology Rats |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA107082-07/CA/NCI NIH HHS; R01 CA130878-03/CA/NCI NIH HHS |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Noninvasive assessment of regulable transferred-p53 gene expression and evaluation of therapeutic re...
Next Document: Signed outside: a surface marker system for transgenic cytoplasmic proteins.